OM
ENTA icon

Opaleye Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Opaleye Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Hold
125,000
– – 0.17% 48
2026
Q1 		$1.58M Buy
125,000
+50,000
+67% +$670K 0.21% 47
2025
Q4 		$1.18M Buy
+75,000
New +$953K 0.16% 49
2017
Q4 		– Sell
-100,000
Closed -$4.68M – 37
2017
Q3 		$4.68M Hold
100,000
– – 1.66% 21
2017
Q2 		$3.6M Hold
100,000
– – 1.5% 20
2017
Q1 		$3.08M Buy
100,000
+10,000
+11% +$311K 1.53% 22
2016
Q4 		$3.02M Buy
+90,000
New +$2.58M 1.78% 21

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Opaleye Management's ENTA Position: Q2 2026 in Review

Opaleye Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 125,000 shares worth $1.82M. The position accounts for 0.17% of the portfolio, ranked #48.

Opaleye Management first reported a position in ENTA in Q4 2016 and has held it in 7 quarters since. The position peaked at $4.68M in Q3 2017. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Opaleye Management held 125,000 shares of Enanta Pharmaceuticals worth $1.82M as of Q2 2026.
  • Opaleye Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
  • Enanta Pharmaceuticals made up 0.17% of Opaleye Management's portfolio in Q2 2026, its #48 holding.
  • Opaleye Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 7 quarters since.
  • Opaleye Management's Enanta Pharmaceuticals position peaked at $4.68M in Q3 2017.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.